These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 18022270

  • 1. Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes.
    Pan H, Han L, Chen W, Yao M, Lu W.
    J Control Release; 2008 Feb 11; 125(3):228-35. PubMed ID: 18022270
    [Abstract] [Full Text] [Related]

  • 2. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC.
    Clin Cancer Res; 2002 Apr 11; 8(4):1172-81. PubMed ID: 11948130
    [Abstract] [Full Text] [Related]

  • 3. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X, Ding L, Xu Y, Wang Y, Ping Q.
    Int J Pharm; 2009 May 21; 373(1-2):116-23. PubMed ID: 19429296
    [Abstract] [Full Text] [Related]

  • 4. Preparation and in vitro targeting of sterically stabilized liposomes modified with chimeric TNT-3 monoclonal antibody.
    Pan H, Niu GQ, Pan J, Lu WY.
    Yao Xue Xue Bao; 2006 Jun 21; 41(6):506-12. PubMed ID: 16927823
    [Abstract] [Full Text] [Related]

  • 5. Enhanced circulation time and antitumor activity of doxorubicin by comblike polymer-incorporated liposomes.
    Han HD, Lee A, Hwang T, Song CK, Seong H, Hyun J, Shin BC.
    J Control Release; 2007 Jul 31; 120(3):161-8. PubMed ID: 17524514
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
    Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW.
    Cancer Res; 2000 Dec 15; 60(24):6950-7. PubMed ID: 11156395
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.
    Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D.
    Cancer Res; 1992 Dec 15; 52(24):6774-81. PubMed ID: 1458465
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes.
    Huang SK, Stauffer PR, Hong K, Guo JW, Phillips TL, Huang A, Papahadjopoulos D.
    Cancer Res; 1994 Apr 15; 54(8):2186-91. PubMed ID: 8174126
    [Abstract] [Full Text] [Related]

  • 12. [Targeting therapy of magnetic doxorubicin liposome in nude mice bearing colon cancer].
    Zhou PH, Yao LQ, Qin XY, Shen XZ, Liu YS, Lu WY, Yao M.
    Zhonghua Yi Xue Za Zhi; 2003 Dec 10; 83(23):2073-6. PubMed ID: 14703420
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.
    Xiang Y, Liang L, Wang X, Wang J, Zhang X, Zhang Q.
    J Control Release; 2011 Jun 30; 152(3):402-10. PubMed ID: 21435361
    [Abstract] [Full Text] [Related]

  • 15. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
    Dubois V, Dasnois L, Lebtahi K, Collot F, Heylen N, Havaux N, Fernandez AM, Lobl TJ, Oliyai C, Nieder M, Shochat D, Yarranton GT, Trouet A.
    Cancer Res; 2002 Apr 15; 62(8):2327-31. PubMed ID: 11956091
    [Abstract] [Full Text] [Related]

  • 16. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
    Bradley MO, Webb NL, Anthony FH, Devanesan P, Witman PA, Hemamalini S, Chander MC, Baker SD, He L, Horwitz SB, Swindell CS.
    Clin Cancer Res; 2001 Oct 15; 7(10):3229-38. PubMed ID: 11595719
    [Abstract] [Full Text] [Related]

  • 17. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
    Wong HL, Rauth AM, Bendayan R, Wu XY.
    Eur J Pharm Biopharm; 2007 Mar 15; 65(3):300-8. PubMed ID: 17156986
    [Abstract] [Full Text] [Related]

  • 18. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.
    van Lummel M, van Blitterswijk WJ, Vink SR, Veldman RJ, van der Valk MA, Schipper D, Dicheva BM, Eggermont AM, ten Hagen TL, Verheij M, Koning GA.
    FASEB J; 2011 Jan 15; 25(1):280-9. PubMed ID: 20876209
    [Abstract] [Full Text] [Related]

  • 19. Streptavidin in antibody pretargeting. 2. Evaluation Of methods for decreasing localization of streptavidin to kidney while retaining its tumor binding capacity.
    Wilbur DS, Hamlin DK, Buhler KR, Pathare PM, Vessella RL, Stayton PS, To R.
    Bioconjug Chem; 1998 Jan 15; 9(3):322-30. PubMed ID: 9576806
    [Abstract] [Full Text] [Related]

  • 20. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA, Hu P, Epstein AL.
    Handb Exp Pharmacol; 2008 Jan 15; (181):291-328. PubMed ID: 18071951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.